

3 October 2023

Treatment of Breast Cancer

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*

Name of Medicine	Number of Patients Treated
1.1 Abemaciclib (Verzenios)	21
1.2 Alpelisib (Piqray)	<5
1.3 Fulvestrant (fulvestrant or Faslodex)	26
1.4 Palbociclib (Ibrance)	36
1.5 Ribociclib (Kisqali)	16

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients received Abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*

Number of Patients Treated
All breast Cancer - 21

3. How many patients received Abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*

Number of Patients Treated
Information not held by Belfast Trust

3 October 2023

4. How many patients received Abemaciclib (Verzenio) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*

Treatment Intent	Number of Patients Treated
4.1 Curative	Information not held by Belfast Trust
4.2 Palliative	Information not held by Belfast Trust
4.3 Not known / stated	Information not held by Belfast Trust

5. How many patients were treated with the following medicines, in combination, in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet*

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenio) + Fulvestrant (fulvestrant or Faslodex)	5
5.2 Abemaciclib (Verzenio) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	<5
5.3 Abemaciclib (Verzenio) + tamoxifen	<5
5.4 Abemaciclib monotherapy	16
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	<5
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	7
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	<5
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	<5

Use of <5 - we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable.